Plain Language Summary of Publication - EORTC 1333/PEACE-3 Study

Sep 28, 2026

Uploaded by SANS

Plain language summary of the EORTC 1333/PEACE-3 study comparing enzalutamide plus androgen deprivation therapy (ADT) alone versus enzalutamide plus ADT combined with radium-223 in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases. The researchers assessed time until radiological progression-free survival, overall time lived, and side effects. Results show improved time without cancer worsening and improved how long patients lived with the combination, with fracture risk monitored through bone-strengthening medication.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages14

Reading Time35 min

AccessFree to download

Where can I find the original article on which this summary is based?

What is this summary about?

What were the results of the study?

What do the results mean?

Future ONCOLOGY Plain Language Summary of Publication A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases Bertrand Tombala, Fred Saadb, Enrique Gallardoc, Andrey Soaresd, Yohann Loriote, Ray McDermottf, Erik Briersg, Mikael Lagströmh, Corneel Coensi, Coralie Ponceti, Beatrice Fournieri & Silke Gillessenj aCliniques universitaires Saint Luc, Brussels, Belgium; bCentre hospitalier de l'Université de Montréal, Montréal, Canada; cParc Taulí Hospital Universitari, Institut d’Investigació I Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, Sabadell, Spain; dEinstein Hospital Israelita, São Paulo, Brazil; eInstitut Gustave Roussy, and Université Paris-Saclay, Paris, France; fTallaght University Hospital, Dublin, Ireland; gEuropean Prostate Cancer Coalition – Europa Uomo, Antwerp, Belgium hÅland, Finland (patient author); iEuropean Organisation of Research and Treatment of Cancer, Brussels, Belgium; jOncology Institute of Southern Switzerland, EOC, Bellinzona, and Università della Svizzera Italiana, Faculty of Biosciences, Lugano, Switzerland First draft submitted: 10 October 2025; Accepted for publication: 17 November 2025 Where can I find the original article on which this summary is based? You can read the original article (in English)‘Enzalutamide plus Radium-223 in Metastatic Castration-Resistant Prostate Cancer: results of the EORTC 1333/PEACE-3 trial’ in Annals of Oncology for free at: [https://www.annalsofoncology.org/article/S0923-7534(25)00203-0/fulltext](https://www.annalsofoncology.org/article/S0923-7534(25)00203-0/fulltext.)[.](https://www.annalsofoncology.org/article/S0923-7534(25)00203-0/fulltext.) What is this summary about? Enzalutamide and radium-223 are two different types of medicines normally used separately to treat prostate cancer that has spread to other parts of the body (metastatic castration-resistant prostate cancer; mCRPC) . Both medicines are usually given with androgen deprivation therapy (ADT) . Radium-223 is only used in people with mCRPC whose cancer has spread to their bones (called bone metastases) . When the study began, enzalutamide was only used to treat patients with castrationresistant disease; nowadays, it is also used to treat earlier stages of prostate cancer that are hormone-sensitive. How to say (download PDF and double click sound icon to play sound) ... • Metastatic: Meh-tuh-STA-tik • Enzalutamide: EN-zuh-LOO-tuh-mide • Radiological: ray-dee-uh-LOJ-uh-kuhl • Progression-free: pruh-GRESH-uhn-free This summary describes the early results of a study called EORTC 1333, or ‘PEACE-3’. The researchers compared enzalutamide plus ADT treatment alone against enzalutamide plus ADT combined with radium-223 in people with mCRPC with bone metastases who had not been treated for mCRPC. Patients, however, may have been treated for earlier stages of prostate cancer. They wanted to see if there was any difference in how long patients lived before their cancer got worse based on medical scans (radiological progression-free survival). They also looked for any difference in how long patients lived and the side effects of combining the two therapies. 10. 1080/14796694 .2025. 2592722 © 2025 The Author(s) . Published by Informa UK Limited, trading as Taylor & Francis Group This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the

FAQs

What treatments were compared in the EORTC 1333/PEACE-3 study?

The study compared enzalutamide plus ADT alone versus enzalutamide plus ADT combined with radium-223 in people with mCRPC and bone metastases.

What outcomes did the researchers look at?

They examined radiological progression-free survival (how long patients lived before cancer worsened on scans), overall how long patients lived, and side effects.

What were the key findings from the results?

Combined treatment showed a trend toward longer time without radiological progression and also improved how long patients lived. Fractures were more common in the combination group, but bone-strengthening medication used during the study helped reduce fracture risk, and most side effects were moderate and manageable.

Sep 28, 2026

Uploaded by SANS